BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bayer readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Bayer's drugs run\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07333183-544@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Mosliciguat: Phase 2 readout est. (NCT07333183)
DESCRIPTION:Mosliciguat\, phase 2\, Pulmonary Hypertension Associated with 
 Interstitial Lung Disease.\nStudy: A Study of Mosliciguat in Combination W
 ith Inhaled Treprostinil in PH-ILD\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/mosliciguat#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073331
 83
URL:https://assetmemo.bio/drug/mosliciguat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05196035-661@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270410
DTEND;VALUE=DATE:20270411
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT05196035)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Chronic Kidney Disease.\nStud
 y: A Study to Learn More About How Well the Study Treatment Finerenone Wor
 ks\, How Safe it is\, How it Moves Into\, Through\, and Out of the Body\, 
 and the Effects it Has on the Body When Taken With an ACE Inhibitor or Ang
 iotensin Receptor Blocker in Children With Chronic Kidney Disease and Prot
 einuria\nEstimated primary completion: 10 April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/finerenone#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05196035
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06452277-2723@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Hyrnuo (Sevabertinib): Phase 3 readout est. (NCT06452277)
DESCRIPTION:Hyrnuo (Sevabertinib)\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Learn More About How Well Sevabertinib Works and How Saf
 e it is Compared With Standard Treatment\, in Participants Who Have Advanc
 ed Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epiderma
 l Growth Factor Receptor 2 (HER2)\nEstimated primary completion: 28 Octobe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/sevabertinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0645
 2277
URL:https://assetmemo.bio/drug/sevabertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988386-11047@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280415
DTEND;VALUE=DATE:20280416
SUMMARY:Attruby (Acoramidis): Phase 3 readout est. (NCT04988386)
DESCRIPTION:Attruby (Acoramidis)\, phase 3.\nStudy: Open-Label Safety Study
  of Acoramidis (AG10) in Symptomatic ATTR Participants\nEstimated primary 
 completion: 15 April 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/acoramidis#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04988386
URL:https://assetmemo.bio/drug/acoramidis#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246643-2058@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280427
DTEND;VALUE=DATE:20280428
SUMMARY:Regorafenib: Phase 2 readout est. (NCT06246643)
DESCRIPTION:Regorafenib\, phase 2.\nStudy: A Study of Continued Treatment W
 ith Regorafenib in Participants With Solid Tumors Who Have Participated in
  Other Bayer Studies\nEstimated primary completion: 27 April 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/regorafenib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06246643
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05457283-661@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280807
DTEND;VALUE=DATE:20280808
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT05457283)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Chronic Kidney Disease.\nStud
 y: A Study to Learn More About How Safe the Study Treatment Finerenone is 
 in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor 
 Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Ye
 ars of Age With Chronic Kidney Disease and Proteinuria\nEstimated primary 
 completion: 7 August 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/finerenone#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05457283
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06944522-1768@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Bemdaneprocel (MSK-DA01): Phase 3 readout est. (NCT06944522)
DESCRIPTION:Bemdaneprocel (MSK-DA01)\, phase 3\, Parkinson's Disease.\nStud
 y: A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adul
 ts Who Have Parkinson's Disease\nEstimated primary completion: October 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/bemdaneprocel-msk-
 da01#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06944522
URL:https://assetmemo.bio/drug/bemdaneprocel-msk-da01#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05099172-2723@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Hyrnuo (Sevabertinib): Phase 1/2 readout est. (NCT05099172)
DESCRIPTION:Hyrnuo (Sevabertinib)\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: First in Human Study of BAY2927088 in Participants Who Have Advan
 ced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epid
 ermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor R
 eceptor 2 (HER2)\nEstimated primary completion: 1 December 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/sevabertinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05099172
URL:https://assetmemo.bio/drug/sevabertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816185-544@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290128
DTEND;VALUE=DATE:20290129
SUMMARY:Mosliciguat: Phase 3 readout est. (NCT07816185)
DESCRIPTION:Mosliciguat\, phase 3\, Pulmonary Hypertension Associated with 
 Interstitial Lung Disease.\nStudy: A Phase 3 Trial of Inhaled Mosliciguat 
 in PH-ILD (PHrontier)\nEstimated primary completion: 28 January 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/mosliciguat#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07816185
URL:https://assetmemo.bio/drug/mosliciguat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06760819-2723@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290202
DTEND;VALUE=DATE:20290203
SUMMARY:Hyrnuo (Sevabertinib): Phase 2 readout est. (NCT06760819)
DESCRIPTION:Hyrnuo (Sevabertinib)\, phase 2.\nStudy: A Study to Learn More 
 About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and
  How Safe it is in Participants Who Have a Solid Tumor With Mutations of t
 he Human Epidermal Growth Factor Receptor 2 (HER2)\nEstimated primary comp
 letion: 2 February 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sevabertinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06760819
URL:https://assetmemo.bio/drug/sevabertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04848506-10786@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Myqorzo (Aficamten): Phase 2/3 readout est. (NCT04848506)
DESCRIPTION:Myqorzo (Aficamten)\, phase 2/3\, Hypertrophic Cardiomyopathy.\
 nStudy: Open-label Extension Study to Evaluate the Long-term Safety and To
 lerability of Aficamten in Adults With HCM\nEstimated primary completion: 
 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aficamten
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT048
 48506
URL:https://assetmemo.bio/drug/aficamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06914128-2381@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290618
DTEND;VALUE=DATE:20290619
SUMMARY:BAY 3713372: Phase 1/2 readout est. (NCT06914128)
DESCRIPTION:BAY 3713372\, phase 1/2.\nStudy: A Study of PRMT5 Inhibitor BAY
  3713372 in Participants With MTAP-deleted Solid Tumors\nEstimated primary
  completion: 18 June 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/bay-3713372#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06914128
URL:https://assetmemo.bio/drug/bay-3713372#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05714085-587@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290820
DTEND;VALUE=DATE:20290821
SUMMARY:Verquvo (Vericiguat): Phase 2/3 readout est. (NCT05714085)
DESCRIPTION:Verquvo (Vericiguat)\, phase 2/3\, Heart Failure.\nStudy: Effic
 acy\, Safety\, and Pharmacokinetics of Vericiguat in Pediatric Participant
 s With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242
 -036)\nEstimated primary completion: 20 August 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/vericiguat#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05714085
URL:https://assetmemo.bio/drug/vericiguat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07188805-661@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07188805)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: A Stud
 y to Learn More About How Well Finerenone Works\, How Safe it is\, and How
  it Moves Into\, Through\, and Out of the Body Compared to Placebo When Ta
 ken With Standard Treatment in Children With Heart Failure and Left Ventri
 cular Systolic Dysfunction\nEstimated primary completion: 30 November 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/finerenone#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07188805
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06412666-10786@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Myqorzo (Aficamten): Phase 2/3 readout est. (NCT06412666)
DESCRIPTION:Myqorzo (Aficamten)\, phase 2/3\, Hypertrophic Cardiomyopathy.\
 nStudy: A Study to Evaluate the Effect of Aficamten in Pediatric Patients 
 With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).\nEstimate
 d primary completion: January 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/aficamten#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06412666
URL:https://assetmemo.bio/drug/aficamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192952-661@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07192952)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: A Stud
 y to Learn More About How Safe Finerenone is\, When it is Taken for a Long
 er Time With Standard Treatment\, in Children and Young Adults With Heart 
 Failure and Left Ventricular Systolic Dysfunction\nEstimated primary compl
 etion: 30 December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/finerenone#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07192952
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563895-11047@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Attruby (Acoramidis): Phase 3 readout est. (NCT06563895)
DESCRIPTION:Attruby (Acoramidis)\, phase 3.\nStudy: Acoramidis Transthyreti
 n Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptoma
 tic Carriers of a Pathogenic TTR Variant\nEstimated primary completion: Oc
 tober 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/acoramidi
 s#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 563895
URL:https://assetmemo.bio/drug/acoramidis#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116473-11047@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20371130
DTEND;VALUE=DATE:20371201
SUMMARY:Attruby (Acoramidis): Phase 3 readout est. (NCT07116473)
DESCRIPTION:Attruby (Acoramidis)\, phase 3\, Transthyretin Amyloidosis with
  Cardiomyopathy.\nStudy: To Evaluate the Long-term Safety and Tolerability
  of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE
 )\nEstimated primary completion: November 2037. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/acoramidis#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07116473
URL:https://assetmemo.bio/drug/acoramidis#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
